Regen BioPharma
4700 Spring Street
Suite 304
La Mesa
California
91942
United States
Tel: 619-702-1404
Fax: 619-330-2328
Website: http://www.regenbiopharma.com/
169 articles about Regen BioPharma
-
Regen BioPharma Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board
10/30/2017
Regen BioPharma announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board.
-
Regen BioPharma Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6
10/23/2017
Regen BioPharma and (OTCQB: RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without the Company's proprietary small molecule drugs bound to it.
-
Regen BioPharma Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases
10/16/2017
Regen BioPharma and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6.
-
Regen BioPharma Researchers Demonstrate Direct Binding Of Proprietary Agonists To Immune Checkpoint NR2F6
10/3/2017
-
Regen BioPharma Issues End Of Fiscal Year Shareholder Letter
9/19/2017
-
Regen BioPharma Researchers Identify Key Structure In Compounds That Activate NR2F6
9/6/2017
-
Regen BioPharma Addresses Potential Impact of Recent Bristol-Myers Squibb's $2.3 Billion Acquisition Of IFM Therapeutics
8/10/2017
-
Regen BioPharma Addresses Potential Impact Of Recent Bristol-Myers Squibb $2.3 Billion Acquisition Of IFM Therapeutics
8/9/2017
-
Regen BioPharma Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators
7/25/2017
-
Regen BioPharma Researchers Discover New Dynamic Compound Which Modulates The NR2F6 Checkpoint
7/12/2017
-
Regen BioPharma Sees Additional Positive Results On Its Medicinal Chemistry Optimization For Modulating NR2F6 Checkpoint For Treating Cancer And Autoimmune Diseases
5/16/2017
-
Regen BioPharma Identifies Three New Series of Compounds That Activate NR2F6
4/18/2017
-
Regen BioPharma Sees Success In Its Pre-Clinical Small Molecule Optimization Program For NR2F6
4/12/2017
-
Regen BioPharma Provides Update On NR2F6 Small Molecule Optimization Program For Treating Cancer And Arthritis
3/24/2017
-
Regen BioPharma Restructures Management Stock Compensation
3/15/2017
-
Regen BioPharma Licenses NR2F6 Technology For Cancer Treatment And Autoimmune Disorders To Checkpoint Immunology
3/2/2017
-
Regen BioPharma Begins Optimization of NR2F6 Small Molecule Modulators
2/1/2017
-
Regen BioPharma Files Utility Patent Application On NR2F6-Silenced CAR-T Cell For Solid Tumors
12/15/2016
-
Regen BioPharma Discusses A Recent Important Discovery Of NR2F6 In Human Cervical Cancer
12/8/2016
-
Regen BioPharma 's Chief Scientific Officer Harry Lander Provides Clarity On The Process Of Small Molecule Development For Cancer And Autoimmune Diseases
11/16/2016